Skip to main content
Signal8

PALISADE BIO, INC. (PALI)

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Palisade Bio, Inc. logo

Palisade Bio, Inc.

NASDAQ:PALIHealthcare
+2.21%$1.16
Mkt Cap$205.22M
Float–
O/S177.68M
VOL58K sh
$ Vol$67K
RVOL0.01×
Inst Own96.7%
Dilution
Palisade Bio, Inc. logoNASDAQ:PALI$1.16+2.21%
Historical Data
DateOpenHighLowCloseVolume
Nov 9, 20261.161.181.151.1658,190
Nov 6, 20261.141.181.101.132,032,623
Nov 5, 20261.221.231.101.162,601,240
Nov 4, 20261.261.301.211.252,016,384
Nov 3, 20261.141.251.131.2318,646,590
Nov 2, 20261.201.201.081.123,073,050
Oct 30, 20261.181.201.111.163,090,603
Oct 29, 20261.201.251.151.193,506,287
Oct 28, 20261.221.221.101.1915,117,655
Oct 27, 20261.221.251.171.206,013,178
Oct 26, 20261.331.351.211.231,704,298
Oct 23, 20261.351.371.281.331,333,929
Oct 22, 20261.381.411.351.351,114,138
Oct 21, 20261.441.461.391.401,433,349
Oct 20, 20261.391.481.331.432,823,241
Oct 19, 20261.411.461.321.341,837,632
Oct 16, 20261.551.561.401.413,889,614
Oct 15, 20261.501.561.481.541,817,613
Oct 14, 20261.451.511.381.484,166,660
Oct 13, 20261.561.581.461.471,588,946
Analyst Coverage
Analyst Coverage
ConsensusBuy
Price Target
Not available
Ratings Distribution
BUY
3
HOLD
0
SELL
0
TOTAL3
Insider Trades
InsiderTypeShares
Capers Julien E. profile photoCapers Julien E.Grant/Award787.3K
Finley John David profile photoFinley John DavidOption Exercise167.6K
Jones Mitchell Lawrence profile photoJones Mitchell LawrenceOption Exercise2.62M
Jones Mitchell Lawrence profile photoJones Mitchell LawrenceAutomatic Sell1.03M
Finley John David profile photoFinley John DavidOption Exercise3.23M
Finley John David profile photoFinley John DavidAutomatic Sell1.41M
Shareholders
96.7%
Institutional
(125)
4.5%
Insiderⓘ
(8)
12.5%
5%+ Owners
(2)
-
Unattributed (incl. retail)ⓘ
Institutional96.7%
Insider4.5%
5%+ Beneficial12.5%
Sources: 13F, Form 4, 13D/13GO/S: 177.7M · as of 6 Oct 2026 · SEC filings
Insiders & Institutional Holders

Insiders

Top institutional holders

About

Palisade Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to identifying, advancing, and bringing to market orally administered treatments for significant conditions stemming from a compromised gastrointestinal mucosal barrier.

The company's primary therapeutic candidate, LB1148, is an oral liquid formulation designed to inhibit digestive enzymes.

Its goal is to safeguard gut integrity when the intestine experiences stress due to factors such as diminished blood supply, infections, or surgical procedures. Established in 2005, the company maintains its headquarters in Carlsbad, California.

Key Metrics
Market Cap$205.22M
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership96.70%

based on 177.68M shares outstanding

SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
CountryUSUS
IPO DateMar 30, 2007
Shares Outstanding177.68M
Authorized Shares
Float–
Float (other source)173.29MPolygon free float · as of 2026-08-14
52-Week Range
$1.08$2.85
$1.16(4th percentile)
Volume
Average Daily Volume3.97M
58.19K today vs 3.97M avg(-99%)

30d Avg

3.97M

60d Avg

3.82M

90d Avg

3.13M

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...